A Phase 1 interventional study of PF-04802540 and Placebo in Healthy, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Singapore. Open to participants aged 21 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-03-19.
Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 1 and Interventional
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to healthy adult subjects.
Evaluation of safety and pharmacokinetics
Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 41 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: PF-04802540
Drug: Placebo
Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
Placebo capsules q12 hours for 10 days
Adverse events
Time frame: 12 days
Safety assessments: vital signs, ECG, physical examination, laboratory tests
Time frame: 12 days
Pharmacokinetics
Time frame: 12 days
No secondary outcomes measures.
Time frame: Timeframe N/A
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taisho Pharmaceutical Co., Ltd.